Changes to Paxlovid® PBS eligibility criteria
Page last updated: 23 June 2023
In an out-of-session consideration, the PBAC has recommended changes to the circumstances under which nirmatrelvir and ritonavir (Paxlovid®) is available on the PBS.
Details of the PBAC’s recommendation can be found on the ‘Recommendations made out-of-session by the PBAC between meetings’ webpage under ‘Recommendations made out-of-session by the Pharmaceutical Benefits Advisory Committee (PBAC) between its March 2023 and July 2023 meetings’.
The Department is working to implement these changes and will provide an update when they are finalised.